PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies

PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes (CTL) that preferentially kill leukemia and contribute to cytogenetic remission. To evaluate safety, immunogenicity and clinical activity of PR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Qazilbash, Muzaffar H., Wieder, Eric, Thall, Peter F., Wang, Xuemei, Rios, Rosa, Lu, Sijie, Kanodia, Shreya, Ruisaard, Kathryn E., Giralt, Sergio A., Estey, Elihu H., Cortes, Jorge, Komanduri, Krishna V., Clise-Dwyer, Karen, Alatrash, Gheath, Ma, Qing, Champlin, Richard E., Molldrem, Jeffrey J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5332281/
https://ncbi.nlm.nih.gov/pubmed/27654852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.254
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados